Parallel Advisors, LLC Relmada Therapeutics, Inc. Transaction History

Parallel Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 20, 2024	BUY	$2.24 - $4.76 $1,303 - $2,770	582 New	582 $1,000
Q1 2023 Apr 25, 2023	SELL	$2.24 - $4.76 $273 - $580	-122 Reduced 17.33%	582 $1,000
Q4 2022 Feb 03, 2023	BUY	$2.17 - $35.84 $1,519 - $25,088	700 Added 17500.0%	704 $2,000
Q3 2022 Nov 10, 2022	BUY	$18.3 - $37.02 $73 - $148	4 New	4 $0
Q4 2021 Jan 20, 2022	SELL	$16.93 - $26.82 $3,115 - $4,934	-184 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$21.86 - $34.77 $4,022 - $6,397	184 New	184 $5,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.3M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.